News
Media
All VideosMedical World NewsPodcastsWeekly RecapCure ConnectionsInsightsSpecial ReportNeurologyLive Peer ExchangeClinical Forum InsightsMedcastPeers & PerspectivesRoundtable DiscussionsShows & Podcasts
Conferences
Conference CoverageConference Listing
CME/CE
More
Partners
Publications
NeurologyLiveBridging the GapsInternational Journal of MS Care
Resources
Expert AuthorsFDA NewsFeaturesFellows' CornerFuture Leaders in NeurologyGiants of Multiple SclerosisInteractive ToolsJob BoardLive EventsNeurology ResourcesSponsoredVirtual Events

Subscribe

  • News
  • Media
  • Conferences
  • CME/CE
  • Partners
  • Publications
  • Resources
  • Subscribe
  • Dementia and Alzheimer Disease
  • Epilepsy
  • Genetic Disorders
  • Headache and Migraine
    • Migraine
  • MS and Demyelinating Disorders
    • NMOSD
    • Multiple Sclerosis
  • Movement Disorders
    • Parkinson Disease
    • Dyskinesia
  • Neuromuscular
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Muscular Dystrophy
    • Ataxia
  • Rare Diseases
  • Sleep Disorders
    • Narcolepsy
    • Excessive Daytime Sleepiness
    • Insomnia
  • Stroke
Spotlight -
Expert Authors|
FDA News|
Upcoming Live Events|
AANEM 2025|
AES 2025|
NSGC 2025
Advertisement

Bruce Trapp, PhD

Advertisement

Articles by Bruce Trapp, PhD

Bruce Trapp, PhD: Insights Gleaned from Myelocortical Multiple Sclerosis

ByBruce Trapp, PhD
June 4th 2019

The chairman of the Department of Neuroscience at the Lerner Research Institute spoke about what the implications of the new subtype of MS could be in the understanding of the disease.

Advertisement

Latest Updated Articles

  • Bruce Trapp, PhD: Insights Gleaned from Myelocortical Multiple Sclerosis
    Bruce Trapp, PhD: Insights Gleaned from Myelocortical Multiple Sclerosis

    Published: June 4th 2019 | Updated:



Advertisement
Advertisement

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

1

Phase 1b Trial for Solid Biosciences’ Friedreich Ataxia Gene Therapy SGT-212 Doses First Patient

2

Efficacy and Safety Data for Tavapadon as an Emerging Therapy in Parkinson’s Disease

3

Phase 3 VALOR Data Further Support Tofersen’s Impact on ALS Disease Progression, Survival

4

Efgartigimod Application Submitted for Seronegative gMG, EC Approves High-Dose Nusinersen, Copper Histidinate Gains First Approval for Menkes Disease

5

Overviewing Emerging Evidence of Vaccines, Dementia Risk, and Pathogen Protection: Pierre Tariot, MD

  • About Us
  • Advisory Board
  • Editorial
  • Contact Us
  • Advertise
  • Contact MJH LS
  • Do Not Sell My Information
  • Terms and Conditions
  • Privacy
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
HCP Live
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us